Fig. 2: Endpoint Sequencing Analysis.
A Highlighter plot of all infected and treatment groups (Untreated, CRISPR-, LA ART-, and Dual-treated with viral rebound) endpoint sequences in the HIV-1NL4_3 env region. Sequences were aligned to the most conserved sample from the HIV-1-infected untreated group [master sequence(m)]. Mutations were color-coded. B Highlighter plot of all samples belonging to all four treatment groups, endpoint sequences in the HIV-1NL4_3 env region with silent (green) and non-silent (red) mutations. C Frequency of mutations detected in gag, pol, and env regions derived from study one (HIV-1NL4_3) endpoint untreated (n = 3), CRISPR-treated (n = 5), LA ART-treated (n = 7–9), and dual-treated and viral rebound samples (n = 5). Statistical comparisons between the different treatment groups were analyzed using one-way ANOVA. Data represent the mean ± standard error for 4 different groups with independent biological replicates.
